Koll, Florestan J.
Döring, Claudia
Olah, Csilla
Szarvas, Tibor
Köllermann, Jens
Hoeh, Benedikt
Chun, Felix K.-H.
Reis, Henning
Wild, Peter J.
Funding for this research was provided by:
Deutsche Krebshilfe
Goethe-Universität Frankfurt am Main (Nachwuchsforscher 2022)
Johann Wolfgang Goethe-Universität, Frankfurt am Main
Article History
Received: 30 January 2023
Accepted: 26 May 2023
First Online: 4 June 2023
Declarations
:
: Tissue/tumor samples and/or patient data used in this study were provided by the University Cancer Center Frankfurt (UCT). Written informed consent was obtained from all patients and the study was approved by the institutional Review Boards of the UCT and the Ethical Committee at the University Hospital Frankfurt (project-number: SUG-6–2018 and UCT-53–2021). The study was conducted according to local and national regulations and according to the Declaration of Helsinki.
: Not applicable.
: HTG Transcriptome Panel was performed as part of a collaboration agreement with HTG Molecular Diagnostics. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results. PJW has received consulting fees and honoraria for lectures by Bayer, Janssen-Cilag, Novartis, Roche, MSD, Astellas Pharma, Bristol-Myers Squibb, Thermo Fisher Scientific, Molecular Health, Guardant Health, Sophia Genetics, Qiagen, Eli Lilly, Myriad, Hedera Dx, and AstraZeneca. Research Support was provided by AstraZeneca and Roche. HR was on an advisory board of Bristol-Myers Squibb, received honoraria from Roche, Bristol-Myers Squibb, Janssen-Cilag, Novartis, Astra-Zeneca, MCI, CHOP GmbH and Diaceutics, received travel support from Philips, Roche, and Bristol-Myers Squibb, and received grants from Bristol-Myers Squibb. All other authors indicate that there are no competing interests.